Information Scan for Jul 11, 2022

US buys 3.2 million doses of Novavax COVID-19 vaccine

The Biden administration introduced this morning that it will purchase 3.2 million doses of the Novavax COVID-19 vaccine, which is predicted to quickly obtain authorization from the Meals and Drug Administration, in keeping with a Division of Well being and Human Providers (HHS) information launch.

The protein-based vaccine can be supplied as a major collection of two photographs. If authorised, it is going to be the fourth COVID-19 vaccine out there to US adults.

The 7-day common of latest day by day COVID-19 circumstances is 111,794, with 327 day by day deaths and 38,149 hospitalized, in keeping with the Washington Publish tracker. Previously week, new day by day circumstances rose 6%, hospitalizations rose 11%, and deaths fell 14%.

With COVID-19 circumstances within the metropolis rising once more, New York Metropolis public well being officers late final week urged residents to return to mask-wearing in indoor public areas, the Related Press reports.

In world information, the European Centre for Illness Prevention and Management (ECDC) and the European Medicines Company are recommending that second booster doses of COVID-19 vaccines be thought of for individuals between 60 and 79 years outdated and individuals who have medical situations placing them at excessive threat of extreme illness.

“The up to date suggestions come amid growing charges of COVID-19 reporting and charges of hospital and intensive care unit (ICU) admissions and occupancy in a number of nations … and within the context of the emergence of the Omicron lineages BA.4 and BA.5. These knowledge sign {that a} new COVID-19 wave is ramping up throughout the European Union/European Financial Space (EU/EEA),” the ECDC mentioned in a press release.
Jul 11 HHS news release
Jul 11 ECDC

COVID vaccine booster—not preliminary routine—key for blood-cancer sufferers

Most sufferers with blood most cancers produced an immune response to the COVID-19 vaccine booster relatively than the preliminary routine, and none given the preventive monoclonal antibody mixture Evusheld have been contaminated, finds a retrospective US examine revealed right this moment in Most cancers.

Brown College researchers led the examine, which concerned evaluation of SARS-CoV-2 antibody ranges and COVID-19 outcomes within the sera of 378 sufferers with hematologic cancers after preliminary and booster vaccine doses. Sufferers who’ve blood cancers corresponding to a number of myeloma, leukemia, and lymphoma are at excessive threat for poor vaccine immune response and extreme COVID-19 outcomes.

Sufferers had acquired boosters after both the two-dose Pfizer/BioNTech or Moderna COVID-19 vaccine, or the one-dose Johnson & Johnson COVID-19 model.

Of the 378 sufferers, 181 (48%) had detectable SARS-CoV-2 antibodies of their sera (seroconverted) after preliminary vaccination. Sufferers with lively most cancers or who had lately acquired an immune-cell–depleting monoclonal antibody have been the least more likely to produce an immune response.

Among the many 85 sufferers whose immune programs did not reply to preliminary vaccination, 48 (56%) developed antibodies after a booster vaccine dose. The outcomes have been related for sufferers who have been and weren’t receiving lively remedy (53% vs 58%).

By the tip of February 2022, 33 sufferers (8.8%) later examined optimistic for COVID-19, and three died of their infections (0.8%). Whereas postvaccination seroconversion and the incidence of an infection weren’t considerably related, no affected person with detectable SARS-CoV-2 antibodies died of COVID-19, and not one of the 25 given AstraZeneca’s tixagevimab-cilgavimab mixture (Evusheld) examined optimistic for the virus.

In a information launch from Wiley, which publishes the journal, first writer Thomas Ollila, MD, mentioned that the findings underscore the significance of encouraging COVID-19 vaccine booster doses and checking antibody ranges in sufferers with blood most cancers to establish who would possibly profit from Evusheld. “That is actual world proof that these actions can save lives,” he mentioned.
Jul 11 Most cancers study
Jul 11 Wiley
news release



Leave a Reply